Your browser is no longer supported. Please, upgrade your browser.
Settings
RIGL Rigel Pharmaceuticals, Inc. daily Stock Chart
RIGL [NASD]
Rigel Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.68 Insider Own0.40% Shs Outstand125.43M Perf Week5.67%
Market Cap327.37M Forward P/E- EPS next Y-0.40 Insider Trans-0.99% Shs Float122.35M Perf Month-3.69%
Income-67.10M PEG- EPS next Q-0.14 Inst Own90.40% Short Float3.08% Perf Quarter-9.06%
Sales18.90M P/S17.32 EPS this Y-26.00% Inst Trans0.03% Short Ratio3.96 Perf Half Y18.64%
Book/sh0.74 P/B3.53 EPS next Y25.90% ROA-73.00% Target Price6.40 Perf Year17.04%
Cash/sh0.78 P/C3.34 EPS next 5Y70.00% ROE-96.20% 52W Range1.94 - 4.38 Perf YTD9.66%
Dividend- P/FCF- EPS past 5Y11.60% ROI-126.80% 52W High-40.41% Beta1.25
Dividend %- Quick Ratio5.80 Sales past 5Y33.80% Gross Margin- 52W Low34.54% ATR0.13
Employees77 Current Ratio5.80 Sales Q/Q-28.00% Oper. Margin- RSI (14)49.69 Volatility4.15% 4.23%
OptionableYes Debt/Eq0.00 EPS Q/Q30.10% Profit Margin- Rel Volume0.73 Prev Close2.55
ShortableYes LT Debt/Eq0.00 EarningsAug 01 AMC Payout- Avg Volume952.37K Price2.61
Recom1.80 SMA20-2.19% SMA501.41% SMA200-3.45% Volume699,657 Change2.35%
Mar-09-17Reiterated H.C. Wainwright Buy $6 → $5
Aug-31-16Reiterated H.C. Wainwright Buy $6 → $7
Aug-30-16Reiterated Piper Jaffray Overweight $10 → $11
Jul-13-16Initiated H.C. Wainwright Buy $6
Jun-13-16Initiated Piper Jaffray Overweight
Apr-22-16Upgrade JP Morgan Neutral → Overweight
Apr-08-13Reiterated Stifel Buy $11 → $7
Nov-29-12Initiated UBS Neutral $9
Nov-06-12Reiterated Oppenheimer Outperform $12 → $15
Mar-26-12Initiated Canaccord Genuity Hold $8
Dec-10-10Downgrade MP Advisors Outperform → Market Perform
Mar-12-10Initiated Piper Jaffray Overweight
Nov-23-09Upgrade RBC Capital Mkts Sector Perform → Outperform
Jul-24-09Downgrade Citigroup Buy → Hold
Jul-10-09Upgrade Boenning & Scattergood Neutral → Outperform $20
Jul-09-09Reiterated RBC Capital Mkts Sector Perform $8 → $16
Jun-16-09Initiated Boenning & Scattergood Neutral
Jun-15-09Reiterated Jefferies & Co Buy $13 → $18
Jun-09-09Initiated Rodman & Renshaw Mkt Outperform $33
Mar-26-09Reiterated Jefferies & Co Buy $21 → $13
Jul-14-17 04:35PM  ETFs with exposure to Rigel Pharmaceuticals, Inc. : July 14, 2017 Capital Cube
Jul-11-17 09:14AM  Rigel Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : RIGL-US : July 11, 2017 Capital Cube
Jun-22-17 05:07PM  Rigel Pharmaceuticals, Inc. Value Analysis (NASDAQ:RIGL) : June 22, 2017 Capital Cube
04:05PM  Rigel Announces Oral Presentation of TAVALISSE (fostamatinib disodium) Phase 3 Clinical Data at the European Hematology Association 22nd Annual Congress PR Newswire
Jun-20-17 11:21AM  Rigel Pharmaceuticals' NDA for Tavalisse Accepted by FDA Zacks
10:19AM  Company News for June 20, 2017 Zacks
08:22AM  Rigel Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : RIGL-US : June 20, 2017 Capital Cube
08:00AM  Today's Research Reports on Stocks to Watch: Rigel Pharmaceuticals and Bellicum Pharmaceuticals Accesswire
Jun-19-17 12:06PM  Here's Why Rigel Pharmaceuticals Inc. Is Shining Extra Bright Today Motley Fool +11.20%
11:10AM  Rigel Pharma Rises Following FDA Approval 24/7 Wall St.
09:08AM  Biotech Movers: Clovis, Seattle Genetics, Rigel TheStreet.com
07:30AM  FDA Accepts Rigel's New Drug Application for TAVALISSE (fostamatinib disodium) for the Treatment of Chronic ITP PR Newswire
Jun-16-17 04:15PM  ETFs with exposure to Rigel Pharmaceuticals, Inc. : June 16, 2017 Capital Cube
08:37AM  Implied Volatility Surging for Rigel Pharmaceuticals (RIGL) Stock Options Zacks
Jun-01-17 07:30AM  Rigel to Present at Jefferies 2017 Global Healthcare Conference PR Newswire
May-31-17 12:44PM  ETFs with exposure to Rigel Pharmaceuticals, Inc. : May 31, 2017 Capital Cube
May-16-17 12:59PM  ETFs with exposure to Rigel Pharmaceuticals, Inc. : May 16, 2017 Capital Cube
May-15-17 04:31PM  3 Biotech Stocks I'd Buy Right Now Motley Fool
May-10-17 08:30AM  Edited Transcript of RIGL earnings conference call or presentation 2-May-17 9:00pm GMT Thomson Reuters StreetEvents
May-05-17 04:30PM  ETFs with exposure to Rigel Pharmaceuticals, Inc. : May 5, 2017 Capital Cube
May-04-17 10:05AM  Rigel Pharmaceuticals, Inc. :RIGL-US: Earnings Analysis: Q1, 2017 By the Numbers : May 4, 2017 Capital Cube
May-03-17 08:45AM  Rigel Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : RIGL-US : May 3, 2017 Capital Cube -7.04%
May-02-17 06:16PM  Rigel reports 1Q loss Associated Press
04:01PM  Rigel Announces First Quarter 2017 Financial Results and Provides Company Update PR Newswire
09:05AM  Investor Network: Rigel Pharmaceuticals, Inc. to Host Earnings Call Accesswire
Apr-27-17 07:30AM  Rigel Announces Tavalisse as Proprietary Name for Fostamatinib in the United States PR Newswire
Apr-25-17 07:30AM  Rigel Announces Conference Call and Webcast to Report First Quarter 2017 Financial Results PR Newswire
Apr-18-17 09:29AM  Rigel Pharmaceuticals Files NDA for Thrombocytopenia Drug Zacks
Apr-17-17 04:05PM  Rigel Submits New Drug Application to FDA for Fostamatinib in Chronic ITP PR Newswire
Mar-31-17 09:18AM  5 Top Breakout Stocks to Boost Your Portfolio Zacks
Mar-27-17 09:00AM  Increased Earnings Estimates Seen for Rigel (RIGL): Can It Move Higher? Zacks +9.58%
Mar-24-17 09:49AM  After Years of Stagnation, Are Shares of Rigel Pharmaceuticals About to Take off Into the Stratosphere? Motley Fool
09:49AM  After Years of Stagnation, Are Shares of Rigel Pharmaceuticals About to Take off Into the Stratosphere? at Motley Fool
06:54AM  Will Rigel Pharmaceuticals (RIGL) Continue to Surge Higher? Zacks
Mar-21-17 08:22AM  3 Beaten-Up Biotech Stocks: Are They Bargains? Motley Fool -8.11%
08:22AM  3 Beaten-Up Biotech Stocks: Are They Bargains? at Motley Fool
Mar-20-17 04:22PM  3 Stocks That Are Ridiculously Cheap Right Now Motley Fool
04:22PM  3 Stocks That Are Ridiculously Cheap Right Now at Motley Fool
Mar-16-17 09:23AM  5 Cheap Breakout Stocks for Superb Returns Zacks
Mar-11-17 01:04PM  RIGEL PHARMACEUTICALS INC Financials
Mar-09-17 11:25AM  Rigel Pharmaceuticals, Inc. :RIGL-US: Earnings Analysis: Q4, 2016 By the Numbers : March 9, 2017 Capital Cube
11:25AM  Rigel Pharmaceuticals, Inc. :RIGL-US: Earnings Analysis: Q4, 2016 By the Numbers : March 9, 2017
Mar-08-17 02:34PM  Edited Transcript of RIGL earnings conference call or presentation 7-Mar-17 10:00pm GMT Thomson Reuters StreetEvents
Mar-07-17 05:14PM  Rigel reports 4Q loss
05:00PM  Rigel Pharmaceuticals Inc Earnings Call scheduled for 5:00 pm ET today
04:14PM  RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:01PM  Rigel Announces Fourth Quarter 2016 and Year End 2016 Financial Results and Provides Company Update PR Newswire
07:07AM  Q4 2016 Rigel Pharmaceuticals Inc Earnings Release - After Market Close
Feb-28-17 07:30AM  Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2016 Financial Results PR Newswire
Feb-24-17 12:57PM  3 Cheap Healthcare Stocks You Can Buy Right Now at Motley Fool
Feb-23-17 09:45AM  [2/23] Today's Top 10 Long/Short Estimize Signal Scores
Feb-08-17 04:18PM  RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh
Feb-03-17 04:01PM  Rigel Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Option To Purchase Additional Shares PR Newswire +9.91%
Jan-31-17 04:23PM  RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:30AM  Rigel Announces Pricing Of Public Offering Of Common Stock PR Newswire
Jan-30-17 04:40PM  RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial +5.05%
04:01PM  Rigel Announces Proposed Public Offering Of Common Stock PR Newswire
12:55PM  Why the Rigel Pharmaceuticals Update Could Signal Further Growth
07:30AM  Fostamatinib Study Results Continue to Trend Positive PR Newswire
Jan-16-17 07:30AM  Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PR Newswire
Jan-05-17 07:30AM  Rigel Provides Business Updates and Preliminary Data in IgA Nephropathy PR Newswire
Dec-14-16 04:02PM  Is Rigel Pharmaceuticals, Inc. (RIGL) Worthy of Your Portfolio? at Insider Monkey
Nov-28-16 06:46PM  Hedge Funds Think The Skys The Limit For Horizon Global Corp (HZN) at Insider Monkey -5.26%
Nov-10-16 07:30AM  Rigel to Present at Jefferies 2016 London Healthcare Conference PR Newswire +6.97%
Nov-04-16 01:02PM  ETFs with exposure to Rigel Pharmaceuticals, Inc. : November 4, 2016 +5.60%
Nov-03-16 10:39AM  Rigel Pharmaceuticals, Inc. :RIGL-US: Earnings Analysis: Q3, 2016 By the Numbers : November 3, 2016
Nov-02-16 07:39PM  Edited Transcript of RIGL earnings conference call or presentation 1-Nov-16 9:00pm GMT
Nov-01-16 05:07PM  Rigel reports 3Q loss
05:00PM  Rigel Pharmaceuticals Inc Earnings Call scheduled for 5:00 pm ET today
04:18PM  RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:01PM  Rigel Announces Third Quarter 2016 Financial Results and Provides Company Update PR Newswire
07:07AM  Q3 2016 Rigel Pharmaceuticals Inc Earnings Release - After Market Close
Oct-28-16 07:30AM  Rigel Announces Conference Call and Webcast to Report Third Quarter 2016 Financial Results PR Newswire
Oct-25-16 10:52AM  Will Teladoc (TDOC) Show Any Improvement in Q3 Earnings?
Oct-23-16 10:15AM  4 Companies That Destroyed Shareholders Last Week at 24/7 Wall St.
Oct-21-16 09:35AM  Rigel Tanks After Late-Stage Drug Failure (RIGL) at Investopedia -5.13%
Oct-20-16 02:24PM  Rigels stock rocked as all-in drug disappoints in late-stage trial at MarketWatch -15.22%
12:35PM  Why Rigel Pharma Is Falling at 24/7 Wall St.
11:48AM  Why Rigel Pharmaceuticals, Inc. Got Hammered Today at Motley Fool
11:45AM  Why Rigel Pharmaceuticals, American Airlines, Facebook, and More Are in the Spotlight at Insider Monkey
07:39AM  Rigel's bleeding disorder drug fails late-stage study
07:17AM  RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure
07:00AM  Rigel Announces Results from the Second FIT Phase 3 Study and the Long-Term Open-Label Extension Study for Fostamatinib in ITP PR Newswire
Oct-19-16 08:41AM  Rigel Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : RIGL-US : October 19, 2016
Oct-11-16 04:57PM  RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh -5.04%
Oct-10-16 10:00PM  Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PR Newswire
Oct-07-16 07:30AM  Rigel Expands Leadership Team in Research and Business Development PR Newswire
Oct-06-16 08:35AM  7 Key FDA Decisions and Clinical Trial Results Coming in Q4 at 24/7 Wall St.
Sep-16-16 12:55PM  Why this Peninsula biotech's layoffs aren't necessarily a bad thing (except for the 46 people losing their jobs) at bizjournals.com
Sep-15-16 10:57AM  Heres Why These Stocks Are Trending Today at Insider Monkey
08:02AM  RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Change in Directors
07:41AM  Rigel Pharmaceuticals cuts 38% of workforce to refocus on fostamatinib at MarketWatch
07:30AM  Rigel Restructures to Focus on Fostamatinib Commercialization PR Newswire
Sep-14-16 09:28AM  Why Rigel Pharmaceuticals' Stock Soared in August at Motley Fool
Sep-01-16 08:37AM  BMO Thinks Rigel's Fostamatinib Market Opportunity Will Be Further Validated
Aug-31-16 11:46AM  ETFs with exposure to Rigel Pharmaceuticals, Inc. : August 31, 2016 -14.25%
08:16AM  Rigel (RIGL) Stock Up on Positive Phase III Fostamatinib Data
Aug-30-16 03:36PM  Rigel Pharma (RIGL) Stock Jumps on Study Results, Piper Jaffray Ups Price Target +48.86%
03:25PM  What The Latest Data Means For Rigel Pharmaceuticals, Inc. (RIGL) at Insider Monkey
12:12PM  Here's Why Rigel Pharmaceuticals, Inc. is Skyrocketing Today at Motley Fool
Rigel Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the discovery and development of drugs in the therapeutic areas of immunology, oncology, and immuno-oncology. The company's clinical programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which has completed Phase III clinical program for immune thrombocytopenia purpura; and Phase II clinical study for autoimmune hemolytic anemia and IgA nephropathy. It is also developing two oncology product candidates, which are in Phase I and Phase II. Rigel Pharmaceuticals, Inc. has license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; Bristol-Myers Squibb Company for the discovery, development, and commercialization of cancer immunotherapies; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of an oncology program; and Daiichi Sankyo to pursue research related to ligases. The company was founded in 1996 and is based in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Duliege Anne-MarieChief Medical OfficerJul 05Sale2.695,00013,4270Jul 07 05:39 PM
Duliege Anne-MarieChief Medical OfficerJan 03Sale2.415,00012,0280Jan 13 06:02 PM
PAYAN DONALD GEVP, Pres. Discovery&ResearchAug 30Sale4.005,30321,21453,031Sep 01 06:18 PM